Evidence map›Paper›PMID 39262417›Full record

ArticleCase reports in rheumatology2023

Usefulness of Sarilumab in Patients with Rheumatoid Arthritis after Regression of Lymphoproliferative Disorders.

Yoshifumi Tada, Akira Maeyama, Tomonobu Hagio, Mariko Sakai, Akihito Maruyama, Takuaki Yamamoto

Erratum issuedAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in rheumatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Yoshifumi TadaDepartment of Rheumatology, Faculty of Medicine, Saga University, Saga, Japan.ORCID https://orcid.org/0000-0003-0742-831X
Akira MaeyamaDepartment of Orthopaedic Surgery, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.ORCID https://orcid.org/0000-0002-3142-7889
Tomonobu HagioDepartment of Orthopaedic Surgery, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Mariko SakaiDepartment of Rheumatology, Faculty of Medicine, Saga University, Saga, Japan.
Akihito MaruyamaDepartment of Rheumatology, Faculty of Medicine, Saga University, Saga, Japan.
Takuaki YamamotoDepartment of Orthopaedic Surgery, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.ORCID https://orcid.org/0000-0001-6187-4957

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lymphoproliferative disorders (LPDs) are serious complications associated with rheumatoid arthritis (RA) treatment that mostly occur during methotrexate (MTX) treatment. Cessation of MTX may induce regression of LPDs but is often followed by a flare of RA. Here, we describe two patients with RA flares after the discontinuation of MTX due to LPDs and sarilumab was useful for the treatment of RA without a relapse of LPDs. Patient 1 was an 84-year-old woman, who developed an LPD in the pharyngeal region after 7 years of MTX treatment. Discontinuation of MTX induced regression of LPD but RA flared within 6 months. Administration of sarilumab, in addition to salazosulfapyridine and prednisolone, reduced the RA activity without LPD relapse. Patient 2 was a 76-year-old man, who developed LPD in the pharyngeal region after 5 years of MTX treatment. Discontinuation of MTX induced regression of LPD, but soon RA flared. Although treatment with tocilizumab (TCZ) was effective in controlling RA, it flared again after 2 years. TCZ was switched to sarilumab and RA was in remission. LPD did not recur during these periods.

Identifiers

PMID39262417
PMCPMC11390195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.